vzphotos/iStock Editorial via Getty Images Back from recent lows, AbbVie ( NYSE: ABBV ) shares reached an all-time high on Wednesday after the Humira developer beat Street forecasts with its Q3 2024 financials as its newer immunology drugs outperformed. For much of 2023, AbbVie's ( NYSE: ABBV ) stock came.
Back to Health Page
